1-3 of 3
A. Schwarer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Frequency of Detection of BCR-ABL Mutations in Imatinib Treated Patients with Chronic Phase CML Who Attain a Complete Cytogenetic Response (CCR) Does Not Diminish with Increasing Duration of CCR but the Associated Loss of Response Is Usually Gradual.

Susan Branford, Z. Rudzki, A. Grigg, J. Seymour, P. Browett, K. Taylor, R. Herrmann, A. Schwarer, C. Arthur, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 271.
https://doi.org/10.1182/blood.V104.11.271.271
Published: 2004
Journal Articles

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

Susan Branford, Z. Rudzki, A. Grigg, J. F. Seymour, K. Taylor, P. Browett, A. Schwarer, K. Bradstock, C. Arthur, S. Durrant, D. Ma, D. Joske, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 274.
https://doi.org/10.1182/blood.V104.11.274.274
Published: 2004
Journal Articles

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

Timothy Hughes, S. Branford, J. Reynolds, J. Seymour, K. Taylor, N. Guzzo-Pernell, R. Filshie, C. Arthur, A. Schwarer, M. Hertzberg, Z. Rudzki, M. Copeman, K. Lynch, A. Grigg
Journal: Blood
Blood (2004) 104 (11): 1001.
https://doi.org/10.1182/blood.V104.11.1001.1001
Published: 2004